INTERVIEW: Sativa Group take an important step forward with controlled drug licence (Directors Talk)

Sativa Group (NEX: SATI) CEO Henry Lees-Buckley joins DirectorsTalk to discuss the award of a Controlled Drug Licence from the UK Home Office. Henry explains why this is an important step forward for the company, what the licence enables the Sativa to do, what it means for the company and why this is such an important achievement.

Sativa Group PLC joined the NEX Exchange on 29th March 2018 as the first UK listed medicinal cannabis investment vehicle. Since then, the Company has changed its business strategy to capitalise on changes in the UK and European laws and regulations surrounding the cannabis industry.

Share on facebook
Share on google
Share on twitter
Share on linkedin

Published on